Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Executives On The Move: Clinical Positions Filled At Gilead, Sanifit and Spectrum, And Ferring Pharma US Officer Is Promoted

Executive Summary

Anti-viral pharma Gilead Sciences, vascular calcification treatment firm Sanifit and hematology and oncology drug developer Spectrum Pharmaceuticals each select a new VP, clinical development. Also, to oversee its group in the US, multinational Ferring Pharmaceuticals promotes its US chief commercial officer to president.

You may also be interested in...



Execs On The Move, June 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Executives On The Move: Boehringer Announces US Promotion, Immatics Chooses A CMO And DalCor Pharma Fills C-Suite Commercial Post

Boehringer Ingelheim announces its BI Pharma president to take helm from retiring US country managing director and chief executive officer. Immunotherapeutics developer Immatics Biotechnologies chooses GSK cell therapy head as CMO, and precision medicine firm DalCor Pharmaceuticals picks a chief commercial officer.

Executives On The Move: Ipsen Decides On New Leader, A CSO for 4P-Pharma And A CFO During Transition for Histogen

Paris, France-based Ipsen decides on a Sanofi Pasteur exec for CEO and Roche Institute head joins cancer and inflammatory therapy company 4P-Pharma as CSO. Meanwhile, regenerative medicine firm Histogen brings on a new CFO during its transition to a public company.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel